Telmisartan

ID: telmisartan

Aliases: Micardis

Type: compound

Route/form: oral

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, non-human/mechanistic, review/regulatory

Source types: human_rct, label, mechanistic, meta_analysis, review

Linked sources: 5

Broad outcomes: Cardiovascular / lipids / blood pressure, Fat loss / metabolic health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• angiotensin II AT1 receptor antagonist
• partial PPAR-gamma agonist

Optimization domains

• hypertension
• cardiometabolic
• renal

Research basis

• Telmisartan is a long-acting ARB with human hypertension outcome context plus PPAR-gamma partial-agonist/mechanistic literature.
• Randomized and meta-analytic data support a possible insulin-sensitivity advantage versus some active antihypertensive comparators, which is why it appears in metabolic-health/PED harm-reduction discussions.
• Best framed as a BP/metabolic-risk drug under monitoring, not as a fat-loss drug.

Limits, risks, and missing evidence

• Hyperkalemia, renal function, hypotension, pregnancy contraindication, and drug-combination issues are central.
• The PPAR-gamma angle is modest and context-dependent, not equivalent to a dedicated body-composition intervention.
• ARB use does not neutralize the cardiovascular risk of stimulants, AAS, clenbuterol, or uncontrolled hypertension.

Risk flags

• approved drug
• blood pressure
• renal potassium monitoring
• pregnancy contraindication

Linked papers, labels, and reviews

1. DailyMed label: telmisartan tablet
   label / dailymed_telmisartan_label
   Official telmisartan label for hypertension; anchors fetal-toxicity, hypotension, renal function, potassium, and interaction cautions.
2. Angiotensin-receptor blocking agents and the PPAR-gamma system
   review / pubmed_telmisartan_ppargamma_2005
   Telmisartan partial PPAR-gamma agonism context.
3. Structural basis for telmisartan-mediated partial activation of PPAR gamma
   mechanistic / nature_telmisartan_ppargamma_structure
   Structural/mechanistic paper.
4. Comparative effects of telmisartan and eprosartan on insulin sensitivity in overweight hypertensive patients
   human_rct / pubmed_telmisartan_insulin_overweight_2009
   Randomized active-comparator study reporting insulin-sensitivity and lipid-profile advantages for telmisartan in overweight hypertensive patients.
5. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients
   meta_analysis / pubmed_telmisartan_insulin_meta_2014
   Meta-analysis of RCTs testing whether telmisartan improves insulin-resistance markers versus active antihypertensive comparators.